Drug intelligence / Profile preview

CKD-393

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Administration: Oral

Overview

CKD-393 is a fixed-dose combination drug developed by Chong Kun Dang Pharmaceutical. It is currently undergoing early-phase clinical trials to evaluate its pharmacokinetic profiles, safety, and tolerability in healthy volunteers. The drug is administered orally.

Beyond the preview

Go deeper on CKD-393.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-393.

Explore the full profile